SynthesisLasers in medical science2025
Thulium laser (1927 nm) for dermatological conditions: a systematic review.
Synthesis in Lasers in medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical and Histopathological Assessment of the Field of Cancerization in Human Skin Before and After Treatment With a 1927-nm Thulium Fractional Laser.Lasers in surgery and medicine · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 1927 nm Thulium laser has emerged as a promising tool for the treatment of dermatological conditions. This systematic review aimed to analyze the efficacy and applicability of this technology. A total of 17 studies were included, involving 448 participants with various dermatological disorders. The results indicated that the 1927 nm laser promoted improvements in skin texture, pigmentation reduction, and scar appearance, with an acceptable of safety profile. On average, treatment protocols included three sessions at monthly intervals and a follow-up of 120 days. Adverse events were mild and transient, although relapses were observed in cases of melasma. There was considerable variability in treatment parameters across studies, and most of them presented a moderate to high risk of bias. Therefore, future research is needed to standardize clinical protocols and confirm long-term effects. Nevertheless, the 1927 nm laser stands out as a valuable dermatological therapeutic resource with the potential to enhance clinical outcomes.
Indexed as
Identifiers
41379329What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.